IDHm cells are thus reliant on glutamate synthesis from glutamine and are particularly sensitive to GLS inhibition in combination with oxidative stress–inducing radiation, revealing a unique therapeutic point of leverage for treating IDHm cancers (McBrayer et al. 2018). The gene discussed is GLS; the disease is cancer.